From
To
Blood donor at donation with red bouncy ball holding in hand.
MONDAY, Sept. 8, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved expanded use of Vonvendi (von Willebrand factor [recombinant]) for routine prophylactic use in adults with all types of the blood-clotting disorder von Willebrand disease (VWD), as well as for on-demand treatment of bleeding episodes and perioperative use in children with VWD.
